(b) Subtract baseline maximum symptom score (t = 0 or pre-inoculation daily max for each symptom) from all other time points, symptom by symptom (e.g., baseline Sneezing is 2, then subtract 2 from all other non-zero Sneezing symptoms from all other time points. If more than 1 pre-inoculation baseline time points available, then adjust for the max pre-inoculation symptom score for each symptom.
(c) If baseline adjusted and unadjusted symptom labels differ, flag for clinical review.
7. Symptom onset is first day of 2 or more consecutive with DailyM axSum of ≥ 2.
* For the purpose of calculating daily symptoms, "calendar days" (e.g midnight to midnight on Wed, 9/3/2014) are used rather than 24 hr periods post inoculation. For calculation of symptom onset, symptom resolution, etc, time relative to inoculation (e.g. +12hrs) is used. (a) Infected if there existed more than 2 measurements that were larger than 1.25, observed at more than 24 hr post inoculation;
Infection/Shedding Status
(b) Infected if there existed more than 1 strong positive measurement that was greater or equal to 3.0, observed at more than 24 hr post inoculation;
(c) PCR data should be calculated based upon standard curves, and expressed in EID50/ml or pfu/ml or pfu-e/ml; 
Five time-specific infection states
Consider the subjects whose titer scores and symptom scores agree, i.e., those who are either infected and symptomatic or uninfected and asymptomatic. We set the infection onset time and offset time for infected subjects as the time point of the first and last occurrence of measurable positive titer > 1.25 for any virus assays defined in section 2.2 respectively. 
Expression profiles of differential pan-viral predictive genes
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Figure 7: Expression profiles of standard pan-viral predictive genes. Average expression profiles of the top 10 % pan-viral predictive genes discovered by the standard predictor averaged over the uninfected subjects (left) and infected subjects (right) in each virus-specific dataset ((A) H3N2, (B) H1N1, (C) HRV, and (D) RSV). The expression levels are normalized such that the maximum and minimum of each gene achieve 1 and −1 respectively.
Prediction of ambiguous subject's state of infection and symptom
In the main text we have we excluded clinically ambiguous subjects due to inconsistencies between their declared symptomatic status and measured shedding status. Here we apply the predictors trained using the unambiguously healthy and unambiguously ill subjects to predict the infected/uninfected states of the ambiguous subjects. These are different predictors trained for each viral challenge. Not surprisingly, the states of the clinically ambiguous subjects are difficult to predict even when using the reference aided classifer. Table 1 shows that, as compared to the standard classifier, the reference aided classifier attains a lower error rate than the standard classifier for H1N1 and HRV but not for the other viral species. However, the reference-aided classifier does achieve a reduction in the average classification error. When averaged over all the different viral species (rows of Table 1 ), the mean prediction accuracies on the uninfected but symptomatic subjects are 0.57 by the standard predictors and 0.49 by the reference-aided predictors. The corresponding mean accuracies on the infected but asymptomatic subjects are 0.66 by the standard predictors and 0.57 by the reference-aided predictors. Table 1 : Average accuracy (error rate) for prediction of infected vs uninfected state for different viral challenges (data from DEE2/DEE5, DEE3/DEE4 and HRV-UVA/HRV-Duke were pooled and designated as H3N2, H1N1, and HRV in table). Shown are the standard predictor (w/o baseline reference), the reference-aided predictor (w/ baseline reference) trained using the unambiguously healthy and unambiguously ill subjects and applied to the ambiguous subjects. The shedding status defined in Sec. 2.2 is used to define the ground truth state of infection. The predictors classify the ambiguous subjects as either infected or uninfected subjects and shown in the Next, we apply the predictors trained using the unambiguously healthy and unambiguously ill subjects to predict the symptomatic/asymptomatic states of the ambiguous subjects. Table 2 shows that, in opposition to Table 1 , the Sx/Asx reference aided predictor reduces the error for H3N2 and RSV but not for H1N1 and HRV. This dichotomy might be partially explained by the fact that symptoms were milder in the H1N1 and HRV cohorts than in the H3N2 and RSV cohorts. Therefore, a larger number of H1N1 and HRV subjects who were clearly infected may not have accurately reported their symptoms.
Unlike for infected state prediction, shown in Table 1 , the referenced based symptom predictor does not reduce the average error when averaged over all viral challenge cohorts. The overall prediction error on all ambiguous subjects is 0.43 using the standard predictors, and 0.49 using the reference-aided predictors. The accuracies on the uninfected but symptomatic subjects are 0.53 by the standard predictors and 0.58 by the reference-aided predictors. The accuracies on the infected but asymptomatic subjects are 0.34 by the standard predictors and 0.43 by the reference-aided predictors. Table 2 : Average accuracy (error rate) for prediction of symptomatic vs asymptomatic state for different viral challenges (data from DEE2/DEE5, DEE3/DEE4 and HRV-UVA/HRV-Duke were pooled and designated as H3N2, H1N1, and HRV in table). Shown are the standard predictor (w/o baseline reference), the reference-aided predictor (w/ baseline reference) trained using the unambiguously healthy and unambiguously ill subjects and applied to the ambiguous subjects to classify the state of symptoms, i.e., the predictors classify the ambiguous subjects as either symptomatic or asymptomatic subjects. The ground truth symptom states of the subjects were determined from self-reported symptoms as described in Sec 2.1. 
